about
Adapting Drug Approval Pathways for Bacteriophage-Based TherapeuticsEconomic evaluations of personalized medicine: existing challenges and current developmentsMolecular biomarkers in idiopathic pulmonary fibrosisThe perils of surrogate endpointsApplying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the futureSoluble biomarkers development in osteoarthritis: from discovery to personalized medicineNonlinguistic Outcome Measures in Adult Cochlear Implant Users Over the First Year of Implantation.Modeling HIV vaccine trials of the future.Validation of a clinical assessment of spectral-ripple resolution for cochlear implant users.Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Characteristics of pediatric pulmonary hypertension trials registered on ClinicalTrials.gov.Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesNew trial designs and potential therapies for pulmonary artery hypertension.Lower levels of sodium intake and reduced cardiovascular risk.Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry.OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational studyDevelopment of drugs for celiac disease: review of endpoints for Phase 2 and 3 trialsAlbuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con ViewOutcome Assessments in Clinical Trials of Cryptococcal Meningitis: Considerations on Use of Early Fungicidal Activity as a Potential Surrogate Endpoint for All-Cause Mortality.Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence.Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.Biomarkers and surrogate endpoints in kidney disease.Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey.Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trialEndoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage.Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine.Sodium, potassium, blood pressure, and cardiovascular disease in humans.Current and advancing treatments for pulmonary arterial hypertension in childhood.Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.Infant formula and neurocognitive outcomes: impact of study end-point selection.Development of macitentan for the treatment of pulmonary arterial hypertension.Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.The genetics of drug efficacy: opportunities and challenges.Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension.
P2860
Q26740597-721289CF-F510-408F-A4D3-29F7A7FD73ABQ26797183-C7D4444A-B33F-49EA-87A2-26E9CB9D32E0Q27025340-0415F5A0-A133-4A8C-A0A5-63A030E5AFC0Q27025740-44462EA7-A60A-466F-B613-2F880ABB9825Q28074451-6D9ECF14-C2AB-4B9B-84EC-7A30BD5A5408Q28077398-C9C00A64-11FF-42E5-9F37-8F7DA568C083Q30357580-B5BEFD2F-6606-466F-91B6-C27115907AC6Q30393307-D71D5F16-BA14-4965-B42E-326D149536E1Q30412999-34117474-3ABD-473F-8488-C209ADA5A123Q33634866-3BAD3241-B932-4B4D-A5AD-948E74A5995EQ33788441-475DE91E-E797-4E36-A89E-4FF252D61FB5Q33788582-48A39127-04D2-4C91-A29A-340B7AE1314FQ33982467-5DDF2AFA-261C-4365-B6C8-7FA3AF2E442FQ34274962-9E7F08E2-ECA0-4DBA-8C2F-5ED31E49C305Q34389992-EB2603B2-C7DE-4D61-BB3E-383464BFC141Q34448350-9AAA80A5-6D02-451D-9FEC-3FA9D3B0D231Q34475498-A27B57DA-D3F5-4432-91A4-5F0DED326F91Q35041528-682C8D4D-63BE-4691-8002-E7E2D91C1A04Q35580144-8497C1BF-B797-4A74-90C0-1DE69A6F35D5Q35682234-35BB4A0D-D4AB-4769-BB45-538175E17D2EQ35984938-96182F17-1F5B-47C9-A3A6-78B93CBBD817Q36094655-7C221CB5-CFF9-4E3D-928D-F26EAA8D3CD1Q36109030-865DBF26-E585-4387-94CD-A9AAD60FDF8EQ36284659-361C5F5B-EEBE-4753-949C-3DFB8E9A7916Q36329179-CAC44867-5006-45C7-AF45-C9521AD63867Q37150891-94CC138F-BCE2-47D2-9373-F15AA71B3A6CQ37476761-B304BFCA-0A46-449D-9294-E2766EAC9912Q37641415-21B669E2-F889-4396-8A5A-6DC573556FB5Q38219892-ABB61BE6-2EF7-4BDF-A561-779CA3A20BB8Q38232339-1CB721A1-37E5-43C5-91D0-391A6D9294EFQ38262877-18F1841C-553F-45DA-AA57-9F83FE51EB3CQ38312486-BCAF9C03-3C44-4F12-AEA0-EAB17B7EC538Q38390841-ABD9C6CA-61E4-4679-B611-D4607A5833ADQ38531008-05FD230B-3B74-4AD1-865D-DD8A5E21F02EQ38545232-1E37F750-E248-440C-B546-3C710AF79C2DQ38561807-B7FE2375-E6CC-496F-8A9D-7B7A4A6EB1CFQ38570060-53237872-9B45-431F-BE19-D26B8BE7E62AQ38696985-942ED40A-00C1-49E0-99DC-BEBF4FD89C0DQ38773033-01282DF6-62F5-4842-A338-3F064FA324DAQ38896631-BDD1F900-2EE6-4618-9C14-5DE2387B490B
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Biomarkers and surrogate endpoints in clinical trials
@ast
Biomarkers and surrogate endpoints in clinical trials
@en
type
label
Biomarkers and surrogate endpoints in clinical trials
@ast
Biomarkers and surrogate endpoints in clinical trials
@en
prefLabel
Biomarkers and surrogate endpoints in clinical trials
@ast
Biomarkers and surrogate endpoints in clinical trials
@en
P2860
P356
P1476
Biomarkers and surrogate endpoints in clinical trials
@en
P2093
John H Powers
Thomas R Fleming
P2860
P304
P356
10.1002/SIM.5403
P407
P577
2012-06-18T00:00:00Z